{"id":"NCT01844505","sponsor":"Bristol-Myers Squibb","briefTitle":"Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)","officialTitle":"A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-06-11","primaryCompletion":"2016-08-01","completion":"2024-04-19","firstPosted":"2013-05-01","resultsPosted":"2017-09-26","lastUpdate":"2025-05-21"},"enrollment":945,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Unresectable or Metastatic Melanoma"],"interventions":[{"type":"BIOLOGICAL","name":"Nivolumab","otherNames":["BMS-936558","MDX-1106"]},{"type":"BIOLOGICAL","name":"Ipilimumab","otherNames":["Yervoy","BMS-734016","MDX-010"]},{"type":"BIOLOGICAL","name":"Placebo for Nivolumab","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo for Ipilimumab","otherNames":[]}],"arms":[{"label":"Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab","type":"EXPERIMENTAL"},{"label":"Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab","type":"EXPERIMENTAL"},{"label":"Arm C: Ipilimumab+Placebo for Nivolumab","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to show that Nivolumab and/or Nivolumab in combination with Ipilimumab will extend progression free survival and overall survival compared to Ipilimumab alone.","primaryOutcome":{"measure":"Progression Free Survival (PFS)","timeFrame":"From randomization until disease progression or death, whichever occurred first (assessed up to February 2015, approximately 20 months)","effectByArm":[{"arm":"Nivolumab","deltaMin":6.87,"sd":null},{"arm":"Nivolumab + Ipilimumab","deltaMin":11.5,"sd":null},{"arm":"Ipilimumab","deltaMin":2.89,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":150,"countries":["United States","Australia","Austria","Belgium","Canada","Czechia","Denmark","Finland","France","Germany","Ireland","Israel","Italy","Netherlands","New Zealand","Norway","Poland","Russia","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["39504507","39282897","34855329","34818112","31562797","30361170","28889792","28662232","28651159","26027431"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","http://www.BMSClinicalTrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":187,"n":313},"commonTop":["Fatigue","Diarrhoea","Pruritus","Nausea","Rash"]}}